ANGO_OUT_1 [2025-04-04 04:27:34 -0400] 2975 Bytes | 835 tokens | Cum: 835 tkns (10.44% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and AngioDynamics (ANGO) hit my radar screen, up to 11.5 from a prev close of 9.82 Do you think its got more juice or is it lacking potential? It's 4:27:34 AM on Fri Apr 04, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: AngioDynamics (ANGO)
IPO: 2004-05-27 (20 Years Ago)
Market Cap: $437,373,616
Shares Outstanding: 40,630,000
Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange: XNAS
Description: AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

Here’s the first list of news for AngioDynamics:

C1 - Apr-03-25 01:13PM - AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands
C2 - Apr-03-25 01:13PM 03:01AM - AngioDynamics Inc (ANGO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
C3 - Apr-02-25 11:50PM - Q3 2025 AngioDynamics Inc Earnings Call
C4 - Apr-02-25 11:50PM 10:20AM - AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript
C5 - Apr-02-25 11:50PM 07:40AM - AngioDynamics (ANGO) Tops Q3 Earnings and Revenue Estimates
C6 - Apr-02-25 11:50PM 06:37AM - AngioDynamics: Fiscal Q3 Earnings Snapshot
C7 - Apr-02-25 11:50PM 06:30AM - AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results
C8 - Mar-31-25 08:00AM - AngioDynamics to Host Virtual Cardiovascular Investor Event

Prior AI Reports for ANGO:
1. 2025-04-02 – Score: 45 – Target: 11.6000 – Highs: 11.7200 / 10.3850 / –
despite-positive-share-performance-companys-financial-health-raises-concerns

(Note: Highs = Same day / 2nd day / 3rd day)

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: AngioDynamics (ANGO).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

ANGO_OUT_3 [2025-04-04 04:27:37 -0400] 431 Bytes | 145 tokens | Cum: 983 tkns (12.29% of 8k)
==========================================================================

Showing C1 (chunk 1 of 1): C1:
**AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands**
Date: Apr-03-25 01:13PM
Source: (Zacks)
URL: /news/17113/angiodynamics-stock-up-on-q3-earnings-beat-gross-margin-expands

**No additional content available.**

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ANGO_OUT_5 [2025-04-04 04:27:38 -0400] 880 Bytes | 271 tokens | Cum: 1302 tkns (16.28% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-03T18:18:00Z - AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands...
A2 - 2025-04-03T16:41:40Z - AngioDynamics, Inc. (NASDAQ:ANGO) Raises Guidance...
A3 - 2025-04-03T09:46:39Z - StoneX Group Inc. Takes $981,000 Position in AngioDynamics, Inc. (NASDAQ:ANGO)...
A4 - 2025-04-03T07:01:19Z - AngioDynamics Inc (ANGO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ......
A5 - 2025-04-02T16:58:00Z - Stocks Erase Early Losses on Strong US Economic News...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ANGO_OUT_7 [2025-04-04 04:27:39 -0400] 1099 Bytes | 303 tokens | Cum: 1607 tkns (20.09% of 8k)
==========================================================================

Showing A1 (chunk 1 of 11): A1:
**AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands**Date: 2025-04-03Source: {'uri': 'nasdaq.com', 'dataType': 'news', 'title': 'NASDAQ Stock Market'}URL: https://www.nasdaq.com/articles/angiodynamics-stock-q3-earnings-beat-gross-margin-expandsAngioDynamics, Inc. ANGO reported an adjusted earnings per share (EPS) of 3 cents for third-quarter fiscal 2025, narrower than the year-ago quarter's adjusted loss per share of 16 cents and the Zacks Consensus Estimate of a loss of 13 cents.

On a pro-forma basis (excluding the divested Dialysis and BioSentry businesses, the divested PICC and Midline product portfolios and the discontinued Radiofrequency and Syntrax products), adjusted loss per share for third-quarter fiscal 2025 was 8 cents, narrower than 16 cents reported in the year-ago quarter.

GAAP loss per share was 11 cents, narrower than the year-ago period's loss per sh

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ANGO_OUT_9 [2025-04-04 04:27:40 -0400] 883 Bytes | 294 tokens | Cum: 1903 tkns (23.79% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-10-09T19:30:00Z - 3 Stocks Insiders Are Buying Heavily in October and Why
B2 - 2024-10-08T18:34:52Z - AngioDynamics Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
B3 - 2024-10-03T15:23:22Z - Why AngioDynamics Stock Is Crashing Today
B4 - 2024-07-16T20:05:27Z - AngioDynamics stock target raised on growth prospects - Investing.com
B5 - 2024-07-11T08:20:13Z - U.S. Autoimmune Disease Diagnostics (Systemic, Localized) Market Size, Share & Trends Analysis Report 2024-2030 - GlobeNewswire
B6 - 2024-05-22T16:18:00Z - AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ANGO_OUT_11 [2025-04-04 04:27:42 -0400] 700 Bytes | 187 tokens | Cum: 2092 tkns (26.15% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Why AngioDynamics Stock Is Crashing Today**Date: Unknown DateSource: Unknown SourceURL: https://www.fool.com/investing/2024/10/03/why-angiodynamics-stock-is-crashing-today/?source=iedfolrf0000001AngioDynamics, a medical technology company, reported mixed results for its fiscal Q1, with revenue slightly missing estimates but adjusted loss per share better than expected. The company maintained its full-year guidance, but its growth prospects are not seen as exciting compared to other stocks.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ANGO_OUT_13 [2025-04-04 04:27:43 -0400] 1117 Bytes | 310 tokens | Cum: 2464 tkns (30.80% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-02 8-K Item 2.02 Results of Oper and Fin Cond.

On April 2, 2025, AngioDynamics, Inc. (AngioDynamics) issued a press release announcing financial results for the fiscal third quarter ended February 28, 2025. A copy of the press release is furnished herewith as Exhibit 9...

S2 - 2025-04-02 8-K Item 2.02 Results of Oper and Fin Cond.

On April 2, 2025, AngioDynamics, Inc. (AngioDynamics) issued a press release announcing financial results for the fiscal third quarter ended February 28, 2025. A copy of the press release is furnished herewith as Exhibit 9...

S3 - 2025-04-02 8-K Item 7.01 Regulation FD Disclosure.

On April 2, 2025, AngioDynamics, Inc. (AngioDynamics) will host the virtual Cardiovascular Investor Event. The presentation slides are furnished herewith as Exhibit 99.1.

The presentation slides furnished pursuant to Item 7.01 of this Form 8-...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ANGO_OUT_15 [2025-04-04 04:27:51 -0400] 1022 Bytes | 260 tokens | Cum: 2726 tkns (34.08% of 8k)
==========================================================================

Showing S2 (chunk 1 of 1): S2:
Item 2.02 Results of Operations and Financial Condition.

On April 2, 2025, AngioDynamics, Inc. (AngioDynamics) issued a press release announcing financial results for the fiscal third quarter ended February 28, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

The information set forth in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that Section. Furthermore, such information shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (the Securities Act), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ANGO_OUT_17 [2025-04-04 04:28:02 -0400] 4999 Bytes | 1380 tokens | Cum: 4243 tkns (53.04% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+----------------------+-------------------------+------------------------+
| Volume: 1,168,807 | Perf Month: 4.91% | Option/Short: Yes / Yes | Sales Y/Y TTM: -12.56% |
+---------------------+----------------------+-------------------------+------------------------+
| Avg Volume: 725.90K | Perf Quarter: 7.21% | Short Float: 4.40% | ROE: -20.46% |
+---------------------+----------------------+-------------------------+------------------------+
| Rel Volume: 1.61 | Index: RUT | Short Ratio: 2.34 | ROI: -21.97% |
+---------------------+----------------------+-------------------------+------------------------+
| RSI (14): 49.96 | Market Cap: 398.76M | Short Interest: 1.70M | Sales Surprise: 2.43% |
+---------------------+----------------------+-------------------------+------------------------+
| ATR (14): 0.61 | Shs Outstand: 40.97M | Beta: 0.58 | EPS Surprise: 38.46% |
+---------------------+----------------------+-------------------------+------------------------+
| SMA20: 2.53% | Shs Float: 38.59M | Sales Q/Q: -4.23% | P/E: - |
+---------------------+----------------------+-------------------------+------------------------+
| SMA50: -4.34% | Inst Own: 81.97% | Sales past 5Y: 2.66% | Earnings: Apr 02 BMO |
+---------------------+----------------------+-------------------------+------------------------+
| SMA200: 19.32% | Insider Own: 4.63% | Employees: 748 | |
+---------------------+----------------------+-------------------------+------------------------+
| Perf Week: -0.10% | Insider Trans: 1.00% | Debt/Eq: 0.02 | |
+---------------------+----------------------+-------------------------+------------------------+

The next section covers any insider trading if any are accessible.

Inside Trans: ANGIODYNAMICS INC (ANGO) by Nighan Warren JR (SVP Quality and Regulatory) on 2025-01-16
- Common Stock: 4060 shares at $12.31 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 286498000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -224721000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 9.82
Average Volume: 641921.45
30-Day High: 10.86
30-Day Low: 8.37

[Detailed Financials: Q2 2025]
- Total Assets: $291,550,000.0
- Total Liabilities: $104,782,000.0
- Total Equity: $186,768,000.0
- Current Assets: $175,360,000.0
- Current Liabilities: $88,595,000.0

[Income Statement: Q2 2025]
- Revenue: $72,845,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.26

[Cash Flow Statement: Q2 2025]
- Net Cash Flow: $-916,000

[Detailed Financials: Q1 2025]
- Total Assets: $293,628,000.0
- Total Liabilities: $97,046,000.0
- Total Equity: $196,582,000.0
- Current Assets: $172,594,000.0
- Current Liabilities: $76,699,000.0

[Income Statement: Q1 2025]
- Revenue: $67,491,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.31

[Cash Flow Statement: Q1 2025]
- Net Cash Flow: $-21,051,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

ANGO_OUT_19 [2025-04-04 04:28:04 -0400] 687 Bytes | 169 tokens | Cum: 4725 tkns (59.06% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

ANGO_IN_21 [2025-04-04 04:28:04 -0400] 126 Bytes | 29 tokens | Cum: 4784 tkns (59.80% of 8k)
==========================================================================

====================================
[2025-04-04 04:28:04] # Analysis Completed
Elapsed Time: 30.50 seconds